Skip to content
2000
image of Recent Alzheimer’s Research Targets Amyloid-β with Novel Phytochemicals and Pharmacological Strategies for Therapy

Abstract

Advances in molecular-level research proposed the Amyloid-β (Aβ) pathway as a pathophysiological centre of Alzheimer’s Disease (AD) progression. The biochemical alterations within the Aβ cycle represent a core biological hallmark of AD and offer promising targets for the development of disease-modifying therapies. However, the precise molecular mechanisms of the Aβ pathway, as well as the spatial and temporal dynamics that drive synaptic dysfunction, neurodegeneration, and the clinical onset of AD, remain active and intensive current research areas. In this work, we provide a comprehensive review and update of the extensive body of research in the field. We analyze data that highlights the differential relationships between various species of Amyloid-β (Aβ) and several biological mechanisms relevant to Alzheimer's Disease (AD), including tau-mediated processes, neuroimmune responses, inflammatory changes, and neurochemical imbalances. This review explores the role of amyloid β, clinical symptoms and mortality, FDA-approved drugs, immunotherapy, and different phytoconstituents used for Aβ-targeting therapy. Phytochemicals show potential in Alzheimer's disease treatment through their antioxidant, anti-inflammatory, and anti-amyloid properties, but challenges with bioavailability and blood-brain barrier permeability remain significant obstacles to their clinical effectiveness.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cas/10.2174/0118746098373086251201095903
2026-03-04
2026-03-08

  • From This Site

    /content/journals/cas/10.2174/0118746098373086251201095903
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Alzheimer’s Disease 2024 Available from: https://www.fda.gov/consumers/health-education-resources/alzheimers-disease
  2. Feigin V.L. Nichols E. Alam T. Global, regional, and national burden of neurological disorders, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019 18 5 459 480 10.1016/S1474‑4422(18)30499‑X 30879893
    [Google Scholar]
  3. Möller H.J. Graeber M.B. The case described by Alois Alzheimer in 1911. Eur. Arch. Psychiatry Clin. Neurosci. 1998 248 3 111 122 10.1007/s004060050027 9728729
    [Google Scholar]
  4. Crous-Bou M. Minguillón C. Gramunt N. Molinuevo J.L. Alzheimer’s disease prevention: From risk factors to early intervention. Alzheimers Res. Ther. 2017 9 1 71 10.1186/s13195‑017‑0297‑z 28899416
    [Google Scholar]
  5. 2024 Alzheimer’s disease facts and figures. Alzheimers Dement. 2024 20 5 3708 3821 10.1002/alz.13809 38689398
    [Google Scholar]
  6. FDA approves new treatment for Alzheimer’s disease. 2023 Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-alzheimers-disease
  7. Budson A.E. Solomon P.R. New criteria for Alzheimer disease and mild cognitive impairment: Implications for the practicing clinician. Neurologist 2012 18 6 356 363 10.1097/NRL.0b013e31826a998d 23114667
    [Google Scholar]
  8. Huang C.Y. Hu C.J. Huang L.K. Chang E.H. Effects of caregiver counselling on medication persistence and adherence in patients with dementia at a pharmacist-managed clinic: A pilot study. J. Clin. Pharm. Ther. 2022 47 12 2074 2082 10.1111/jcpt.13752 36543253
    [Google Scholar]
  9. Howell B.M. Piech A. Wolfe C. A pilot of a communication program for dementia caregivers using improvisational techniques. Gerontol. Geriatr. Med. 2022 8 23337214221123733 10.1177/23337214221123733 36134037
    [Google Scholar]
  10. Soria Lopez J.A. González H.M. Léger G.C. Alzheimer’s Disease. Handb. Clin. Neurol. 2019 167 231 255 10.1016/B978‑0‑12‑804766‑8.00013‑3
    [Google Scholar]
  11. Glenner G.G. Wong C.W. Alzheimer’s disease and Down’s syndrome: Sharing of a unique cerebrovascular amyloid fibril protein. Biochem. Biophys. Res. Commun. 1984 122 3 1131 1135 10.1016/0006‑291X(84)91209‑9 6236805
    [Google Scholar]
  12. Glenner G.G. Wong C.W. Alzheimer’s disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 1984 120 3 885 890 10.1016/S0006‑291X(84)80190‑4 6375662
    [Google Scholar]
  13. Brion J.P. Couck A.M. Passareiro E. Flament-Durand J. Neurofibrillary tangles of Alzheimer’s disease: An immunohistochemical study. J. Submicrosc. Cytol. 1985 17 1 89 96 [PMID: 3973960
    [Google Scholar]
  14. Grundke-Iqbal I. Iqbal K. Tung Y.C. Quinlan M. Wisniewski H.M. Binder L.I. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. USA 1986 83 13 4913 4917 10.1073/pnas.83.13.4913 3088567
    [Google Scholar]
  15. Pollock N. Mirra S. Binder L. Hansen L. Wood J. Filamentous aggregates in Pick’s disease, progressive supranuclear palsy, and Alzheimer’s disease share antigenic determinants with microtubule-associated protein, tau. Lancet 1986 328 8517 1211 10.1016/S0140‑6736(86)92212‑9 2430155
    [Google Scholar]
  16. Khan S. Barve K.H. Kumar M.S. Recent advancements in pathogenesis, diagnostics, and treatment of Alzheimer’s disease. Curr. Neuropharmacol. 2020 18 11 1106 1125 10.2174/1570159X18666200528142429 32484110
    [Google Scholar]
  17. Wagner S.L. Tanzi R.E. Mobley W.C. Galasko D. Potential use of γ-secretase modulators in the treatment of Alzheimer disease. Arch. Neurol. 2012 69 10 1255 1258 10.1001/archneurol.2012.540 22801784
    [Google Scholar]
  18. Sperling R.A. Aisen P.S. Beckett L.A. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011 7 3 280 292 10.1016/j.jalz.2011.03.003 21514248
    [Google Scholar]
  19. Varshney M. Kumar B. Varshney P. Kumar Lal D. Sethiya N.K. In-vitro and in-silico examinations on baicalein-loaded solid lipid nanoparticles for neurodegeneration. Drug Deliv. Lett. 2024 14 2 151 164 10.2174/0122103031263883231230085819
    [Google Scholar]
  20. Arya R.K.K. Vijay J. Bisht D. Enhanced brain delivery via intranasal administration of carbamazepine loaded solid lipid nanoparticles: Optimization, pharmacokinetic analysis, in-vitro, and in-vivo drug release study. Curr. Drug Deliv. 2023 20 5 587 600 10.2174/1567201819666220519120837 35598246
    [Google Scholar]
  21. Sethiya N.K. Nahata A. Singh P.K. Mishra S.H. Neuropharmacological evaluation on four traditional herbs used as nervine tonic and commonly available as Shankhpushpi in India. J. Ayurveda Integr. Med. 2019 10 1 25 31 10.1016/j.jaim.2017.08.012 29530454
    [Google Scholar]
  22. Sethiya N.K. Mishra S.H. Investigation of mangiferin, as a promising natural polyphenol xanthone on multiple targets of Alzheimer’s disease. Journal of Biologically Active Products from Nature 2014 4 2 111 119 10.1080/22311866.2014.921121
    [Google Scholar]
  23. Sethiya N.K. Nahata A. Dixit V.K. Mishra S.H. Cognition boosting effect of Canscora decussata (a South Indian Shankhpushpi). Eur. J. Integr. Med. 2012 4 1 e113 e121 10.1016/j.eujim.2011.11.003
    [Google Scholar]
  24. Kumari N. Anand S. Shah K. Chauhan N.S. Sethiya N.K. Singhal M. Emerging role of plant-based bioactive compounds as therapeutics in parkinson’s disease. Molecules 2023 28 22 7588 10.3390/molecules28227588 38005310
    [Google Scholar]
  25. Sethiya N.K. Ghiloria N. Srivastava A. Therapeutic potential of myricetin in the treatment of neurological, neuropsychiatric neurodegenerative disorder. CNS Neurol. Disord. Drug Targets 2024 23 7 865 882 10.2174/1871527322666230718105358
    [Google Scholar]
  26. Varshney M. Kumar B. Rana V.S. Sethiya N.K. An overview on therapeutic and medicinal potential of poly-hydroxy flavone viz. Heptamethoxyflavone, Kaempferitrin, Vitexin and Amentoflavone for management of Alzheimer’s and Parkinson’s diseases: a critical analysis on mechanistic insight. Crit. Rev. Food Sci. Nutr. 2023 63 16 2749 2772 10.1080/10408398.2021.1980761 34590507
    [Google Scholar]
  27. Walia V. Chaudhary S.K. Kumar Sethiya N. Therapeutic potential of mangiferin in the treatment of various neuropsychiatric and neurodegenerative disorders. Neurochem. Int. 2021 143 104939 10.1016/j.neuint.2020.104939 33346032
    [Google Scholar]
  28. Sethiya N.K. Sharma S. Shah K. Chauhan D.N. Chauhan N.S. Current Trends and Future Prospects of Natural Products in Neurodegenerative Disorders. Natural Scaffolds for Prevention and Treatment of Neurodegenerative Disorders. CRC Press 2025 29
    [Google Scholar]
  29. Tiwari S. Atluri V. Kaushik A. Yndart A. Nair M. Alzheimer’s disease: Pathogenesis, diagnostics, and therapeutics. Int. J. Nanomedicine 2019 14 5541 5554 10.2147/IJN.S200490 31410002
    [Google Scholar]
  30. Murphy M.P. LeVine H. Alzheimer’s disease and the amyloid-beta peptide. J. Alzheimers Dis. 2010 19 1 311 323 10.3233/JAD‑2010‑1221 20061647
    [Google Scholar]
  31. Chen J.X. Yan S.S. Role of mitochondrial amyloid-β in Alzheimer’s disease. J Alzheimers Dis 2010 20 s2 S569 S578.(Suppl. 2) 10.3233/JAD‑2010‑100357 20463403
    [Google Scholar]
  32. Crews L. Masliah E. Molecular mechanisms of neurodegeneration in Alzheimer’s disease. Hum. Mol. Genet. 2010 19 R1 R12 R20 10.1093/hmg/ddq160 20413653
    [Google Scholar]
  33. Armstrong R.A. The molecular biology of senile plaques and neurofibrillary tangles in Alzheimer’s disease. Folia Neuropathol. 2009 47 4 289 299 [PMID: 20054780
    [Google Scholar]
  34. Chen G. Xu T. Yan Y. Amyloid beta: Structure, biology and structure-based therapeutic development. Acta Pharmacol. Sin. 2017 38 9 1205 1235 10.1038/aps.2017.28 28713158
    [Google Scholar]
  35. Tabaton M. Piccini A. Role of water‐soluble amyloid‐β in the pathogenesis of Alzheimer’s disease. Int. J. Exp. Pathol. 2005 86 3 139 145 10.1111/j.0959‑9673.2005.00428.x 15910548
    [Google Scholar]
  36. Zhang H. Wei W. Zhao M. Interaction between Aβ and Tau in the pathogenesis of Alzheimer’s disease. Int. J. Biol. Sci. 2021 17 9 2181 2192 10.7150/ijbs.57078 34239348
    [Google Scholar]
  37. Hampel H. Hardy J. Blennow K. The Amyloid-β pathway in Alzheimer’s disease. Mol. Psychiatry 2021 26 10 5481 5503 10.1038/s41380‑021‑01249‑0 34456336
    [Google Scholar]
  38. Breijyeh Z. Karaman R. Comprehensive review on Alzheimer’s disease: Causes and treatment. Molecules 2020 25 24 5789 10.3390/molecules25245789 33302541
    [Google Scholar]
  39. Bloom G.S. Amyloid-β and Tau. JAMA Neurol. 2014 71 4 505 508 10.1001/jamaneurol.2013.5847 24493463
    [Google Scholar]
  40. Gulisano W. Maugeri D. Baltrons M.A. Role of Amyloid-β and Tau Proteins in Alzheimer’s Disease: Confuting the Amyloid Cascade. J. Alzheimers Dis. 2018 64 s1 S611 S631 10.3233/JAD‑179935 29865055
    [Google Scholar]
  41. Tönnies E. Trushina E. Oxidative stress, synaptic dysfunction, and Alzheimer’s disease. J. Alzheimers Dis. 2017 57 4 1105 1121 10.3233/JAD‑161088 28059794
    [Google Scholar]
  42. Chen Z. Zhong C. Oxidative stress in Alzheimer’s disease. Neurosci. Bull. 2014 30 2 271 281 10.1007/s12264‑013‑1423‑y 24664866
    [Google Scholar]
  43. Monteiro A.R. Barbosa D.J. Remião F. Silva R. Alzheimer’s disease: Insights and new prospects in disease pathophysiology, biomarkers and disease-modifying drugs. Biochem. Pharmacol. 2023 211 115522 10.1016/j.bcp.2023.115522 36996971
    [Google Scholar]
  44. Ionescu-Tucker A. Cotman C.W. Emerging roles of oxidative stress in brain aging and Alzheimer’s disease. Neurobiol. Aging 2021 107 86 95 10.1016/j.neurobiolaging.2021.07.014 34416493
    [Google Scholar]
  45. Zvěřová M. Alzheimer’s disease and blood-based biomarkers – Potential contexts of use. Neuropsychiatr. Dis. Treat. 2018 14 1877 1882 10.2147/NDT.S172285 30050302
    [Google Scholar]
  46. Becker J.T. Neuropsychological explorations of memory and cognition: Essays in honor of Nelson Butters. Plenum Press. Cermak L. New York, NY Springer 1994 103 116
    [Google Scholar]
  47. Cahn D.A. Salmon D.P. Bondi M.W. A population-based analysis of qualitative features of the neuropsychological test performance of individuals with dementia of the Alzheimer type: Implications for individuals with questionable dementia. J. Int. Neuropsychol. Soc. 1997 3 4 387 393 10.1017/S1355617797003871 9260448
    [Google Scholar]
  48. Apostolova L.G. Alzheimer disease. Continuum (N. Y.) 2016 28 3 648 675 10.1212/CON.0000000000000307
    [Google Scholar]
  49. Houmani N. Vialatte F. Gallego-Jutglà E. Diagnosis of Alzheimer’s disease with electroencephalography in a differential framework. PLoS One 2018 13 3 e0193607 10.1371/journal.pone.0193607 29558517
    [Google Scholar]
  50. Zvěřová M. Clinical aspects of Alzheimer’s disease. Clin. Biochem. 2019 72 3 6 10.1016/j.clinbiochem.2019.04.015 31034802
    [Google Scholar]
  51. Ferri C.P. Prince M. Brayne C. Global prevalence of dementia: A Delphi consensus study. Lancet 2005 366 9503 2112 2117 10.1016/S0140‑6736(05)67889‑0 16360788
    [Google Scholar]
  52. Mayeux R. Stern Y. Epidemiology of Alzheimer disease. Cold Spring Harb. Perspect. Med. 2012 2 8 a006239 10.1101/cshperspect.a006239 22908189
    [Google Scholar]
  53. Nakahori N. Sekine M. Yamada M. Tatsuse T. Kido H. Suzuki M. Future projections of the prevalence of dementia in Japan: results from the Toyama Dementia Survey. BMC Geriatr. 2021 21 1 602 10.1186/s12877‑021‑02540‑z 34702187
    [Google Scholar]
  54. Ren R. Qi J. Lin S. The China Alzheimer Report 2022. Gen. Psychiatr. 2022 35 1 e100751 10.1136/gpsych‑2022‑100751 35372787
    [Google Scholar]
  55. World Alzheimer Report 2018 London ADI 2018
    [Google Scholar]
  56. Nichols E. Szoeke C.E.I. Vollset S.E. Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019 18 1 88 106 10.1016/S1474‑4422(18)30403‑4 30497964
    [Google Scholar]
  57. Wolters F.J. Chibnik L.B. Waziry R. Twenty-seven-year time trends in dementia incidence in Europe and the United States: The Alzheimer Cohorts Consortium. Neurology 2020 95 5 e519 e531 10.1212/WNL.0000000000010022 32611641
    [Google Scholar]
  58. Dementia. 2024 Available from: https://www.who.int/news-room/fact-sheets/detail/dementia
  59. Alzheimer’s Disease Facts and Figures 2024 Available from: https://www.alz.org/alzheimers-dementia/facts-figures
  60. World Alzheimer Report. 2023 Available from: https://www.alzint.org/resource/world-alzheimer-report-2023/
  61. Wu Y.T. Beiser A.S. Breteler M.M.B. The changing prevalence and incidence of dementia over time — current evidence. Nat. Rev. Neurol. 2017 13 6 327 339 10.1038/nrneurol.2017.63 28497805
    [Google Scholar]
  62. Prince M. Ali G.C. Guerchet M. Prina A.M. Albanese E. Wu Y.T. Recent global trends in the prevalence and incidence of dementia, and survival with dementia. Alzheimers Res. Ther. 2016 8 1 23 10.1186/s13195‑016‑0188‑8 27473681
    [Google Scholar]
  63. Liang C.S. Li D.J. Yang F.C. Mortality rates in Alzheimer’s disease and non-Alzheimer’s dementias: A systematic review and meta-analysis. Lancet Healthy Longev. 2021 2 8 e479 e488 10.1016/S2666‑7568(21)00140‑9 36097997
    [Google Scholar]
  64. Lv B. Liang L. Chen A. Mortality of AD and other dementias in China: Past and Future Decades. Int. J. Public Health 2023 68 1605129 10.3389/ijph.2023.1605129 36816830
    [Google Scholar]
  65. Chen R. Charpignon M.L. Raquib R.V. Excess mortality with Alzheimer disease and related dementias as an underlying or contributing cause during the COVID-19 pandemic in the US. JAMA Neurol. 2023 80 9 919 928 10.1001/jamaneurol.2023.2226 37459088
    [Google Scholar]
  66. Rajamaki B. Hartikainen S. Tolppanen A.M. The effect of comorbidities on survival in persons with Alzheimer’s disease: A matched cohort study. BMC Geriatr. 2021 21 1 173 10.1186/s12877‑021‑02130‑z 33750334
    [Google Scholar]
  67. Tanzi R.E. FDA approval of aduhelm paves a new path for AD. ACS Chem. Neurosci. 2021 12 15 2714 2715 10.1021/acschemneuro.1c00394 34259498
    [Google Scholar]
  68. Haddad H.W. Malone G.W. Comardelle N.J. Aduhelm, a novel anti-amyloid monoclonal antibody, for the treatment of Alzheimer’s Disease: A comprehensive review. Health Psychol. Res. 2022 10 2 10.52965/001c.37023
    [Google Scholar]
  69. Geldmacher D.S. Donepezil (Aricept®) for treatment of Alzheimer’s disease and other dementing conditions. Expert Rev. Neurother. 2004 4 1 5 16 10.1586/14737175.4.1.5 15853610
    [Google Scholar]
  70. Hussien R.M. Shoukry A.A. Rivastigmine patch (Exelon patch) compared to melatonin patch in prevention of postoperative delirium in the elderly. Ain-Shams J Anesthesiol 2020 12 1 37 10.1186/s42077‑020‑00087‑6
    [Google Scholar]
  71. Kurkinen M.T. Lecanemab (Leqembi) is not the right drug for patients with Alzheimer’s disease. Adv. Clin. Exp. Med. 2023 32 9 943 947 10.17219/acem/171379 37676096
    [Google Scholar]
  72. Leqembi granted traditional approval for Alzheimer disease. Neurology Advisor. 2023 Available from: https://www.neurologyadvisor.com/features/aducanumab-lecanemab-early-ad-clinical-trials-fda-approval/
  73. Farlow M.R. Tariot P. Grossberg G.T. Gergel I. Grahm S. Jin J. Memantine/donepezil dual therapy is superior to placebo/donepezil therapy for treatment of moderate to severe Alzheimer’s disease. Neurology 2003 60 A412
    [Google Scholar]
  74. Quetiapine R.E. Namenda slows cognitive decline in Alzheimer’s disease. Available from: https://www.psychiatrictimes.com/view/namenda-slows-cognitive-decline-in-ad
  75. Greig S.L. Memantine ER/donepezil: A review in AD. CNS Drugs 2015 29 11 963 970 10.1007/s40263‑015‑0287‑2 26519339
    [Google Scholar]
  76. Gold M. Lilienfeld S. Truyen L. Long-term benefits of galantamine (Reminyl®) in Alzheimer’s disease. Expert Rev. Neurother. 2004 4 1 13 21 10.1586/14737175.4.1.13
    [Google Scholar]
  77. van Dyck C.H. Swanson C.J. Aisen P. Lecanemab in early Alzheimer’s disease. N. Engl. J. Med. 2023 388 1 9 21 10.1056/NEJMoa2212948 36449413
    [Google Scholar]
  78. Sevigny J. Chiao P. Bussière T. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature 2016 537 7618 50 56 10.1038/nature19323 27582220
    [Google Scholar]
  79. Budd Haeberlein S. Aisen P.S. Barkhof F. Two randomized phase 3 studies of aducanumab in early Alzheimer’s disease. J. Prev. Alzheimers Dis. 2022 9 2 197 210 10.14283/jpad.2022.30 35542991
    [Google Scholar]
  80. Vandenberghe R. Rinne J.O. Boada M. Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials. Alzheimers Res. Ther. 2016 8 1 18 10.1186/s13195‑016‑0189‑7 27176461
    [Google Scholar]
  81. Honig L.S. Vellas B. Woodward M. Trial of solanezumab for mild dementia due to Alzheimer’s disease. N. Engl. J. Med. 2018 378 4 321 330 10.1056/NEJMoa1705971 29365294
    [Google Scholar]
  82. Doody R.S. Thomas R.G. Farlow M. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N. Engl. J. Med. 2014 370 4 311 321 10.1056/NEJMoa1312889 24450890
    [Google Scholar]
  83. Bateman R.J. Smith J. Donohue M.C. GRADUATE I and II investigators and the gantenerumab study group. Two phase 3 trials of gantenerumab in early Alzheimer’s disease. N. Engl. J. Med. 2023 389 20 1862 1876 10.1056/NEJMoa2304430 37966285
    [Google Scholar]
  84. Mintun M.A. Lo A.C. Duggan Evans C. Donanemab in early Alzheimer’s disease. N. Engl. J. Med. 2021 384 18 1691 1704 10.1056/NEJMoa2100708 33720637
    [Google Scholar]
  85. Series C.C. New Alzheimer’s Genes Reinforce Known Pathways. AInternational Conference on Alzheimer’s and Parkinson’s Diseases. Lisbon, Portugal 2019 1 97
    [Google Scholar]
  86. Farlow MR Jessen F Wietek S Melsen T Haag S Dodel R P3‐283: Randomized double‐blind placebo‐controlled dose‐finding trial of intravenous immunoglobulin (octagam® 10%, octapharma AG) in patients with Alzheimer’s disease. Alzheimers Dement 2010 6 4S_Part_17 S534 10.1016/j.jalz.2010.05.1783
    [Google Scholar]
  87. Li J. Haj Ebrahimi A. Ali A.B. Advances in therapeutics to alleviate cognitive decline and neuropsychiatric symptoms of AD. Int. J. Mol. Sci. 2024 25 10 5169 10.3390/ijms25105169 38791206
    [Google Scholar]
  88. Brookmeyer R. Corrada M.M. Curriero F.C. Kawas C. Survival following a diagnosis of Alzheimer disease. Arch. Neurol. 2002 59 11 1764 1767 10.1001/archneur.59.11.1764 12433264
    [Google Scholar]
  89. Graff-Radford J. Yong K.X.X. Apostolova L.G. New insights into atypical Alzheimer’s disease in the era of biomarkers. Lancet Neurol. 2021 20 3 222 234 10.1016/S1474‑4422(20)30440‑3 33609479
    [Google Scholar]
  90. Minoshima S Cross D Thientunyakit T Foster NL Drzezga A 18F-FDG PET imaging in neurodegenerative dementing disorders: insights into subtype classification, emerging disease categories, and mixed dementia with copathologies. J Nucl Med 2022 63 2S 12S.(Suppl. 1). 10.2967/jnumed.121.263194 35649653
    [Google Scholar]
  91. Ossenkoppele R. Schonhaut D.R. Schöll M. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease. Brain 2016 139 5 1551 1567 10.1093/brain/aww027 26962052
    [Google Scholar]
  92. Ossenkoppele R. Pichet Binette A. Groot C. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nat. Med. 2022 28 11 2381 2387 10.1038/s41591‑022‑02049‑x 36357681
    [Google Scholar]
  93. Hansson O. Seibyl J. Stomrud E. CSF biomarkers of Alzheimer’s disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement. 2018 14 11 1470 1481 10.1016/j.jalz.2018.01.010 29499171
    [Google Scholar]
  94. Wattmo C. Blennow K. Hansson O. Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease. BMC Neurol. 2020 20 1 10 10.1186/s12883‑019‑1591‑0 31918679
    [Google Scholar]
  95. Bucci M. Chiotis K. Nordberg A. Alzheimer’s disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline. Mol. Psychiatry 2021 26 10 5888 5898 10.1038/s41380‑021‑01263‑2 34593971
    [Google Scholar]
  96. Sitek E.J. Barczak A. Kluj-Kozłowska K. Kozłowski M. Barcikowska M. Sławek J. Is descriptive writing useful in the differential diagnosis of logopenic variant of primary progressive aphasia, Alzheimer’s disease and mild cognitive impairment? Neurol. Neurochir. Pol. 2015 49 4 239 244 10.1016/j.pjnns.2015.06.001 26188940
    [Google Scholar]
  97. Mattsson-Carlgren N. Janelidze S. Palmqvist S. Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease. Brain 2020 143 11 3234 3241 10.1093/brain/awaa286 33068398
    [Google Scholar]
  98. Ashton N.J. Benedet A.L. Pascoal T.A. Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer’s disease. EBioMedicine 2022 76 103836 10.1016/j.ebiom.2022.103836 35158308
    [Google Scholar]
  99. Dubois B. von Arnim C.A.F. Burnie N. Bozeat S. Cummings J. Biomarkers in Alzheimer’s disease: role in early and differential diagnosis and recognition of atypical variants. Alzheimers Res. Ther. 2023 15 1 175 10.1186/s13195‑023‑01314‑6 37833762
    [Google Scholar]
  100. Jiang Y. Gao H. Turdu G. Traditional Chinese medicinal herbs as potential AChE inhibitors for anti-Alzheimer’s disease: A review. Bioorg. Chem. 2017 75 50 61 10.1016/j.bioorg.2017.09.004 28915465
    [Google Scholar]
  101. Wojtunik-Kulesza K.A. Targowska-Duda K. Klimek K. Volatile terpenoids as potential drug leads in Alzheimer’s disease. Open Chem. 2017 15 1 332 343 10.1515/chem‑2017‑0040
    [Google Scholar]
  102. Suganthy N. Pandima Devi K. Protective effect of catechin rich extract of Rhizophora mucronata against β-amyloid-induced toxicity in PC12 cells. J. Appl. Biomed. 2016 14 2 137 146 10.1016/j.jab.2015.10.003
    [Google Scholar]
  103. Okello E.J. Mather J. Comparative kinetics of acetyl- and butyryl-cholinesterase inhibition by green tea catechins: Relevance to the symptomatic treatment of Alzheimer’s disease. Nutrients 2020 12 4 1090 10.3390/nu12041090 32326457
    [Google Scholar]
  104. Ahmad I. Aqil F. Owais M. Modern phytomedicine: turning medicinal plants into drugs. Hoboken, NJ, USA 2006 10.1002/9783527609987
    [Google Scholar]
  105. Atul Bhattaram V Graefe U Kohlert C Veit M Derendorf H. Pharmacokinetics and bioavailability of herbal medicinal products. Phytomedicine 2002 9 1 33.(Suppl. 3) 10.1078/1433‑187X‑00210 12222652
    [Google Scholar]
  106. Salehi B. Sharifi-Rad J. Cappellini F. The therapeutic potential of anthocyanins: Current approaches based on their molecular mechanism of action. Front. Pharmacol. 2020 11 1300 10.3389/fphar.2020.01300 32982731
    [Google Scholar]
  107. Leyva-Gómez G. Cortés H. Magaña J.J. Leyva-García N. Quintanar-Guerrero D. Florán B. Nanoparticle technology for treatment of Parkinson’s disease: the role of surface phenomena in reaching the brain. Drug Discov. Today 2015 20 7 824 837 10.1016/j.drudis.2015.02.009 25701281
    [Google Scholar]
  108. Islam M.S. Quispe C. Hossain R. Neuropharmacological effects of quercetin: A literature-based review. Front. Pharmacol. 2021 12 665031 10.3389/fphar.2021.665031 34220504
    [Google Scholar]
  109. Kreuter J. Drug delivery to the central nervous system by polymeric nanoparticles: What do we know? Adv. Drug Deliv. Rev. 2014 71 2 14 10.1016/j.addr.2013.08.008 23981489
    [Google Scholar]
  110. Wang X. Perumalsamy H. Kwon H.W. Na Y.E. Ahn Y.J. Effects and possible mechanisms of action of acacetin on the behavior and eye morphology of Drosophila models of Alzheimer’s disease. Sci. Rep. 2015 5 1 16127 10.1038/srep16127 26530776
    [Google Scholar]
  111. Han B.H. Cofell B. Everhart E. Amentoflavone promotes cellular uptake and degradation of amyloid-beta in neuronal cells. Int. J. Mol. Sci. 2022 23 11 5885 10.3390/ijms23115885 35682567
    [Google Scholar]
  112. Nikbakht F. Khadem Y. Haghani S. Protective role of apigenin against Aβ 25-35 toxicity via inhibition of mitochondrial cytochrome c release. Basic Clin. Neurosci. 2019 10 6 557 566 [PMID: 32477473
    [Google Scholar]
  113. Wang D. Li S. Chen J. Liu L. Zhu X. The effects of astilbin on cognitive impairments in a transgenic mouse model of Alzheimer’s disease. Cell. Mol. Neurobiol. 2017 37 4 695 706 10.1007/s10571‑016‑0405‑9 27435287
    [Google Scholar]
  114. Wei D. Tang J. Bai W. Wang Y. Zhang Z. Ameliorative effects of baicalein on an amyloid-β induced Alzheimer’s disease rat model: A proteomics study. Curr. Alzheimer Res. 2014 11 9 869 881 [PMID: 25274114
    [Google Scholar]
  115. Chen X. Yang Y. Zhang Y. Isobavachalcone and bavachinin from Psoraleae Fructus modulate Aβ42 aggregation process through different mechanisms in vitro. FEBS Lett. 2013 587 18 2930 2935 10.1016/j.febslet.2013.07.037 23907009
    [Google Scholar]
  116. Aishwarya V. Sumathi T. Chrysin, a natural flavonoid, attenuates cognitive dysfunction and neuronal loss associated with amyloid β (25–35)-induced oxidative stress: An experimental model of Alzheimer’s disease. Int. J. Pharmacogn. Phytochem. Res. 2015 7 2 224 236
    [Google Scholar]
  117. Zhang Z. Liu X. Schroeder J.P. 7,8-dihydroxyflavone prevents synaptic loss and memory deficits in a mouse model of Alzheimer’s disease. Neuropsychopharmacology 2014 39 3 638 650 10.1038/npp.2013.243 24022672
    [Google Scholar]
  118. Sun P. Yin J.B. Liu L.H. Protective role of Dihydromyricetin in Alzheimer’s disease rat model associated with activating AMPK/SIRT1 signaling pathway. Biosci. Rep. 2019 39 1 BSR20180902 10.1042/BSR20180902 30498091
    [Google Scholar]
  119. Sawmiller D. Habib A. Li S. Diosmin reduces cerebral Aβ levels, tau hyperphosphorylation, neuroinflammation, and cognitive impairment in the 3xTg-AD mice. J. Neuroimmunol. 2016 299 98 106 10.1016/j.jneuroim.2016.08.018 27725131
    [Google Scholar]
  120. Zeng P. Fang M. Zhao H. Guo J. A network pharmacology approach to uncover the key ingredients in Ginkgo Folium and their anti-Alzheimer’s disease mechanisms. Aging 2021 13 14 18993 19012 10.18632/aging.203348 34315132
    [Google Scholar]
  121. Lee D. Kim N. Jeon S.H. Hesperidin improves memory function by enhancing neurogenesis in a mouse model of Alzheimer’s disease. Nutrients 2022 14 15 3125 10.3390/nu14153125 35956303
    [Google Scholar]
  122. Zheng L. Wu S. Jin H. Molecular mechanisms and therapeutic potential of icariin in the treatment of Alzheimer’s disease. Phytomedicine 2023 116 154890 10.1016/j.phymed.2023.154890 37229892
    [Google Scholar]
  123. Delgado A. Cholevas C. Theoharides T.C. Neuroinflammation in Alzheimer’s disease and beneficial action of luteolin. Biofactors 2021 47 2 207 217 10.1002/biof.1714 33615581
    [Google Scholar]
  124. Feng S.T. Wang Z.Z. Yuan Y.H. Sun H.M. Chen N.H. Zhang Y. Mangiferin: A multipotent natural product preventing neurodegeneration in Alzheimer’s and Parkinson’s disease models. Pharmacol. Res. 2019 146 104336 10.1016/j.phrs.2019.104336 31271846
    [Google Scholar]
  125. Du Z. Fanshi F. Lai Y.H. Mechanism of anti-dementia effects of mangiferin in a senescence accelerated mouse (SAMP8) model. Biosci. Rep. 2019 39 9 BSR20190488 10.1042/BSR20190488 31484797
    [Google Scholar]
  126. Li J. Xiang H. Huang C. Lu J. Pharmacological actions of myricetin in the nervous system: A comprehensive review of preclinical studies in animals and cell models. Front. Pharmacol. 2021 12 797298 10.3389/fphar.2021.797298 34975495
    [Google Scholar]
  127. Kimura A.M. Tsuji M. Yasumoto T. Myricetin prevents high molecular weight Aβ1-42 oligomer-induced neurotoxicity through antioxidant effects in cell membranes and mitochondria. Free Radic. Biol. Med. 2021 171 232 244 10.1016/j.freeradbiomed.2021.05.019 34015458
    [Google Scholar]
  128. Choi G.Y. Kim H.B. Hwang E.S. Naringin enhances long-term potentiation and recovers learning and memory deficits of amyloid-beta induced Alzheimer’s disease-like behavioral rat model. Neurotoxicology 2023 95 35 45 10.1016/j.neuro.2022.12.007 36549596
    [Google Scholar]
  129. Nakajima A. Ohizumi Y. Potential benefits of nobiletin, a citrus flavonoid, against Alzheimer’s disease and Parkinson’s disease. Int. J. Mol. Sci. 2019 20 14 3380 10.3390/ijms20143380 31295812
    [Google Scholar]
  130. Nakajima A. Aoyama Y. Shin E.J. Nobiletin, a citrus flavonoid, improves cognitive impairment and reduces soluble Aβ levels in a triple transgenic mouse model of Alzheimer’s disease (3XTg-AD). Behav. Brain Res. 2015 289 69 77 10.1016/j.bbr.2015.04.028 25913833
    [Google Scholar]
  131. Rasool M. Malik A. Waquar S. In-Silico Characterization and in-Vivo Validation of Albiziasaponin-A, Iso-Orientin, and Salvadorin Using a Rat Model of Alzheimer’s Disease. Front. Pharmacol. 2018 9 730 10.3389/fphar.2018.00730 30123124
    [Google Scholar]
  132. Liu R. Li J. Song J. Pinocembrin improves cognition and protects the neurovascular unit in Alzheimer related deficits. Neurobiol. Aging 2014 35 6 1275 1285 10.1016/j.neurobiolaging.2013.12.031 24468471
    [Google Scholar]
  133. Sohanaki H. Baluchnejadmojarad T. Nikbakht F. Roghani M. Pelargonidin improves memory deficit in amyloid β25-35 rat model of Alzheimer’s disease by inhibition of glial activation, cholinesterase, and oxidative stress. Biomed. Pharmacother. 2016 83 85 91 10.1016/j.biopha.2016.06.021 27470554
    [Google Scholar]
  134. Xian Y.F. Ip S.P. Lin Z.X. Mao Q.Q. Su Z.R. Lai X.P. Protective effects of pinostrobin on β-amyloid-induced neurotoxicity in PC12 cells. Cell. Mol. Neurobiol. 2012 32 8 1223 1230 10.1007/s10571‑012‑9847‑x 22565301
    [Google Scholar]
  135. Shi L. Chen B. Gao M. The characteristics of therapeutic effect of pinocembrin in transient global brain ischemia/reperfusion rats. Life Sci. 2011 88 11-12 521 528 10.1016/j.lfs.2011.01.011 21262238
    [Google Scholar]
  136. Zeng Y.Q. Cui Y.B. Gu J.H. Liang C. Zhou X.F. Scutellarin mitigates Aβ-induced neurotoxicity and improves behavior impairments in AD mice. Molecules 2018 23 4 869 10.3390/molecules23040869 29642616
    [Google Scholar]
  137. Guo L. Guan Z. Wang Y. Scutellarin protects against Aβ-induced learning and memory deficits in rats: involvement of nicotinic acetylcholine receptors and cholinesterase. Acta Pharmacol. Sin. 2011 32 12 1446 1453 10.1038/aps.2011.115 21986571
    [Google Scholar]
  138. Kiris I. Skalicka-Wozniak K. Basar M.K. Sahin B. Gurel B. Baykal A.T. Molecular effects of pteryxin and scopoletin in the 5xFAD Alzheimer’s disease mouse model. Curr. Med. Chem. 2022 29 16 2937 2950 10.2174/0929867328666210827152914 34455957
    [Google Scholar]
  139. Sun W. Kawahata I. Xu H. Oral sinensetin, but not nobiletin alone, prevents MK 801-induced impairment of memory formation in mice, like nobiletin‐rich chinpi, a kampo medicine. Tradit. Kampo Med. 2017 4 2 116 120 10.1002/tkm2.1076
    [Google Scholar]
  140. Xiong Y. Deng Z. Liu J. Enhancement of epithelial cell autophagy induced by sinensetin alleviates epithelial barrier dysfunction in colitis. Pharmacol. Res. 2019 148 104461 10.1016/j.phrs.2019.104461 31542404
    [Google Scholar]
  141. Bao J. Liang Z. Gong X. Tangeretin inhibits BACE1 activity and attenuates cognitive impairments in AD model mice. J. Agric. Food Chem. 2022 70 5 1536 1546 10.1021/acs.jafc.1c07241 35084179
    [Google Scholar]
  142. Hung W.L. Chiu T.H. Wei G.J. Neuroprotective effects of nobiletin and tangeretin against amyloid β1-42-induced toxicity in cultured primary rat neurons. Nutrire 2023 48 2 56 10.1186/s41110‑023‑00241‑8
    [Google Scholar]
  143. Jang S.W. Liu X. Yepes M. A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone. Proc. Natl. Acad. Sci. USA 2010 107 6 2687 2692 10.1073/pnas.0913572107 20133810
    [Google Scholar]
  144. Williams C.M. El Mohsen M.A. Vauzour D. Blueberry-induced changes in spatial working memory correlate with changes in hippocampal CREB phosphorylation and brain-derived neurotrophic factor (BDNF) levels. Free Radic. Biol. Med. 2008 45 3 295 305 10.1016/j.freeradbiomed.2008.04.008 18457678
    [Google Scholar]
  145. Zhao L. Li D. Qi X. Potential of food-derived bioactive peptides in alleviation and prevention of Alzheimer’s disease. Food Funct. 2022 13 21 10851 10869 10.1039/D2FO02278H 36219143
    [Google Scholar]
  146. Godos J. Caraci F. Castellano S. Association between dietary flavonoid intake and cognitive function in an Italian cohort. Biomolecules 2021 11 5 698 10.3390/biom11050698 34067181
    [Google Scholar]
  147. Alhodieb F.S. Rahman M.A. Barkat M.A. Nanomedicine-driven therapeutic interventions of autophagy and stem cells in the management of Alzheimer’s disease. Nanomedicine 2023 18 2 145 168 10.2217/nnm‑2022‑0108 36938800
    [Google Scholar]
  148. Ansari M.A. Tripathi T. Venkidasamy B. Multifunctional Nanocarriers for Alzheimer’s Disease. Befriending the Barriers 2024 61 3042 3089
    [Google Scholar]
  149. Cummings J. Lee G. Ritter A. Sabbagh M. Zhong K. Alzheimer’s disease drug development pipeline: 2020. Alzheimers Dement. 2020 6 1 e12050 10.1002/trc2.12050 32695874
    [Google Scholar]
  150. Sen S. Chakraborty R. Toward the integration and advancement of herbal medicine: A focus on traditional Indian medicine. Botanics 2015 5 33 44 10.2147/BTAT.S66308
    [Google Scholar]
  151. Park S.Y. Potential therapeutic agents against Alzheimer’s disease from natural sources. Arch. Pharm. Res. 2010 33 10 1589 1609 10.1007/s12272‑010‑1010‑y 21052936
    [Google Scholar]
  152. Dhage P.A. Sharbidre A.A. Dakua S.P. Balakrishnan S. Leveraging hallmark Alzheimer’s molecular targets using phytoconstituents: Current perspective and emerging trends. Biomed. Pharmacother. 2021 139 111634 10.1016/j.biopha.2021.111634 33965726
    [Google Scholar]
  153. Brewer G.J. Copper excess, zinc deficiency, and cognition loss in Alzheimer’s disease. Biofactors 2012 38 2 107 113 10.1002/biof.1005 22438177
    [Google Scholar]
  154. Bohrmann B. Baumann K. Benz J. Gantenerumab: A novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β. J. Alzheimers Dis. 2012 28 1 49 69 10.3233/JAD‑2011‑110977 21955818
    [Google Scholar]
  155. Logovinsky V. Satlin A. Lai R. Safety and tolerability of BAN2401 - A clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody. Alzheimers Res. Ther. 2016 8 1 14 10.1186/s13195‑016‑0181‑2 27048170
    [Google Scholar]
  156. Salloway S. Sperling R. Fox N.C. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N. Engl. J. Med. 2014 370 4 322 333 10.1056/NEJMoa1304839 24450891
    [Google Scholar]
  157. Osborne O.M. Naranjo O. Heckmann B.L. Dykxhoorn D. Toborek M. Anti-amyloid: An antibody to cure Alzheimer’s or an attitude. Mol. Neurodegener. 2023 18 1 45 10.1186/s13024‑023‑00638‑9 37415149
    [Google Scholar]
  158. Schneider L. A resurrection of aducanumab for Alzheimer’s disease. Lancet Neurol. 2020 19 2 111 112 10.1016/S1474‑4422(19)30480‑6 31978357
    [Google Scholar]
  159. Kocis P. Tolar M. Yu J. Elucidating the Aβ42 anti-aggregation mechanism of action of tramiprosate in Alzheimer’s disease: Integrating molecular analytical methods, pharmacokinetic and clinical data. CNS Drugs 2017 31 6 495 509 10.1007/s40263‑017‑0434‑z 28435985
    [Google Scholar]
  160. Tolar M. Abushakra S. Hey J.A. Porsteinsson A. Sabbagh M. Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval. Alzheimers Res. Ther. 2020 12 1 95 10.1186/s13195‑020‑00663‑w 32787971
    [Google Scholar]
  161. Singh A.V. Ansari M.H.D. Rosenkranz D. Artificial intelligence and machine learning in computational nanotoxicology: Unlocking and empowering nanomedicine. Adv. Healthc. Mater. 2020 9 17 1901862 10.1002/adhm.201901862 32627972
    [Google Scholar]
  162. Singh A.V. Maharjan R.S. Kanase A. Machine-learning-based approach to decode the influence of nanomaterial properties on their interaction with cells. ACS Appl. Mater. Interfaces 2021 13 1 1943 1955 10.1021/acsami.0c18470 33373205
    [Google Scholar]
  163. Borderud S.P. Li Y. Burkhalter J.E. Sheffer C.E. Ostroff J.S. Electronic cigarette use among patients with cancer: Characteristics of electronic cigarette users and their smoking cessation outcomes. Cancer 2014 120 22 3527 3535 10.1002/cncr.28811 25252116
    [Google Scholar]
  164. Ansari M.H.D. Lavhale S. Kalunke R.M. Recent advances in plant nanobionics and nanobiosensors for toxicology applications. Curr. Nanosci. 2020 16 1 27 41 10.2174/1573413715666190409101305
    [Google Scholar]
  165. Tiwari Pandey A. Pandey I. Zamboni P. Traditional herbal remedies with a multifunctional therapeutic approach as an implication in COVID-19 associated co-infections. Coatings 2020 10 8 761 10.3390/coatings10080761
    [Google Scholar]
  166. Vikram Singh A. Sigloch H. Laux P. Luch A. Wagener S. Tentschert J. Micro/nanoplastics: An emerging environmental concern for the future decade. Frontiers in Nanoscience and Nanotechnology 2021 7 1 1 2 10.15761/FNN.1000191
    [Google Scholar]
  167. Kamphuis P.J.G.H. Scheltens P. Can nutrients prevent or delay onset of Alzheimer’s disease? J. Alzheimers Dis. 2010 20 3 765 775 10.3233/JAD‑2010‑091558 20182021
    [Google Scholar]
  168. Agunloye O.M. Oboh G. Falade A.O. Pleurotus ostreatus and Lentinus subnudus supplemented diets restore altered acetylcholinesterase and butyrylcholinesterase activities and improve antioxidant status in transgenic Drosophila melanogaster model. J. Diet. Suppl. 2021 18 4 372 386 10.1080/19390211.2020.1772441 32496927
    [Google Scholar]
  169. Falcon C. Tucholka A. Monté-Rubio G.C. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer’s disease: A study of two independent datasets. Neuroimage Clin. 2018 19 190 201 10.1016/j.nicl.2018.04.016 30023169
    [Google Scholar]
  170. Counts S.E. Ikonomovic M.D. Mercado N. Vega I.E. Mufson E.J. Biomarkers for the early detection and progression of Alzheimer’s disease. Neurotherapeutics 2017 14 1 35 53 10.1007/s13311‑016‑0481‑z 27738903
    [Google Scholar]
  171. Love M.N. Clark D.G. Cochran J.N. Den Beste K.A. Geldmacher D.S. Benzinger T.L. Clinical, imaging, pathological, and biochemical characterization of a novel presenilin 1 mutation. Neurobiol. Aging 2017 49 216
    [Google Scholar]
  172. Knopman D.S. Amieva H. Petersen R.C. Alzheimer disease. Nat. Rev. Dis. Primers 2021 7 1 33 10.1038/s41572‑021‑00269‑y 33986301
    [Google Scholar]
  173. Pathak C. Kabra U.D. A comprehensive review of multi-target directed ligands in the treatment of Alzheimer’s disease. Bioorg. Chem. 2024 144 107152 10.1016/j.bioorg.2024.107152 38290187
    [Google Scholar]
/content/journals/cas/10.2174/0118746098373086251201095903
Loading
Recent Alzheimer’s Research Targets Amyloid-β with Novel Phytochemicals and Pharmacological Strategies for Therapy
Bentham Science Publishers ; https://doi.org/10.2174/0118746098373086251201095903
/content/journals/cas/10.2174/0118746098373086251201095903
/content/journals/cas/10.2174/0118746098373086251201095903
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: neurofibrillary tangles ; Alzheimer’s disease (AD) ; tau ; antioxidant ; beta amyloid ; amyloid plaques

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test